{"id":"NCT03867201","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients","officialTitle":"A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-26","primaryCompletion":"2021-08-11","completion":"2024-04-30","firstPosted":"2019-03-07","resultsPosted":"2025-05-11","lastUpdate":"2025-05-11"},"enrollment":557,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"BIOLOGICAL","name":"Erenumab","otherNames":["AMG334"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Erenumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.","primaryOutcome":{"measure":"Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period","timeFrame":"baseline (4 weeks period prior to start of study drug), week 9 to 12","effectByArm":[{"arm":"Erenumab 70 mg","deltaMin":-8.19,"sd":0.46},{"arm":"Placebo","deltaMin":-6.62,"sd":0.45}],"pValues":[{"comp":"OG000 vs OG001","p":"0.015"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":63,"countries":["China","India","Malaysia","Philippines","Singapore","South Korea","Taiwan","Thailand","Vietnam"]},"refs":{"pmids":["36404301"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":279},"commonTop":["Upper respiratory tract infection","COVID-19","Constipation","Dizziness","Nasopharyngitis"]}}